Home' Australian Pharmacist : Australian Pharmacist September 2014 Contents Australian Pharmacist September 2014 I ©Pharmaceutical Society of Australia Ltd.
Global OTC trends
Nicholas Hall, an internationally
recognised expert in the non-
prescription medicines industry, will
discuss Global over-the-counter (OTC)
trends, insights and future drivers at the
ASMI 2014 Conference on 18 November.
ASMI Executive Director Deon
Schoombie said that: ‘Nicholas will
focus on emerging trends in the global
and regional OTC market, and how
multinational and Asia-Pacific players
can learn from international best
practice, as well as create their own
business models and success strategies.
‘Nicholas will be sharing vital
information including the latest research
findings and insights gained from
40 years of working with top OTC players
globally,’ Mr Schoombie said.
A recent study completed by Nicholas
Hall Group and Nielsen explored
self-medication trends in four South East
Asian markets (Indonesia, Philippines,
Thailand and Vietnam). The report
described the emergence of a new
consumer class in South East Asia who
are sophisticated and discerning.
Figures published by Nicholas Hall & Co
revealed that sales of OTC medicines
in Asia-Pacific reached US$40 billion in
2013, representing close to one-third of
global OTC sales (32%). The Asia-Pacific
region experienced growth of
4.5% in 2013, compared with 4.7%.
This weakened performance was mainly
because of slower growth in China and
India while Japan continued to stagnate.
The Nicholas Hall Group of Companies
(NHC) was established 36 years ago
and is now the leading independent
marketing consultancy and business
intelligence network specialising in
Bone density testing clinics
Discount Drug Stores (DDS) will run bone
density clinics in 110 of its stores again this
year to help Australians to pick up on the
early warning signs of osteoporosis.
The clinics follow its inaugural clinics in
2013, which, the company says, proved
highly successful in catching the warning
signs of osteoporosis and bone disease,
testing more than 2,000 people and
referring more than half to their local
doctor for further investigation.
The clinics are also timely following new
findings from the Australian Bureau of
Statistics showing one in four Australians
are vitamin D deficient.
Professional Services Manager at Discount
Drug Stores Casey Clark said: ‘We want to
help people to take real preventive action
against the disease by helping them to
make positive lifestyle changes before
it’s too late. You can’t see or feel your
bones getting thinner so these tests are
important in determining if an individual is
at risk before their bones become so brittle
that even a small bump or minor fall can
cause a fracture.’
At the clinic each participant will receive
information about the benefits of calcium,
vitamin D and exercise, fill out a simple
questionnaire so their specific risk factors
can be determined, and perform a quick
and simple ultrasonic bone density test.
Participants will then sit with a clinician
who will go over their results and
personal risk factors, discussing the best
preventative measures and treatments.
‘ The bone density test is quick and
painless and allows customers to gain
their results instantly,’ Ms Clark said.
‘Participants will also receive completely
tailored advice on their risks of
osteoporosis and how to prevent the
disease to assist in the maintenance of
The bone density testing clinics will run
through September and cost $29.99.
Each customer will receive a gift bag
valued at $20 containing a resistance
band, a pack of Ostelin 30 and a
Mirvaso Gel (brimonidine tartrate gel
0.5%) has been approved for use in the
treatment of facial erythema associated
with rosacea by the Therapeutic Goods
Administration (TGA). The registration
enables GPs and dermatologists to
provide another treatment option for
the condition. Up to 1.6 million people
in Australia are affected by rosacea, a
chronic inflammatory skin condition
that has a wider reaching impact than
being a cosmetic problem.
Treatment results show that Mirvaso
Gel can reduce facial redness from
30 minutes after application and the
effects can last up to 12 hours. Mirvaso
Gel is a vasoconstrictor that works by
narrowing the blood vessels of the
face which reduces excess blood flow
and therefore reduces facial redness.
It has been approved for use in people
over the age of 18 years who are
suffering from facial redness associated
The approved dosing of Mirvaso Gel is
up to 1 gram, divided into five small
pea sized amounts split evenly across
the five areas of the face: forehead,
both cheeks, nose and chin. Its efficacy
in treating moderate to severe facial
erythema of rosacea is supported by
two comprehensive studies involving
553 adults. Baseline disease severity was
graded using both a 5 point Clinician
Erythema Assessment (CEA) scale and
Patient Self-Assessment scale (PSA),
on which participants scored either
‘moderate’ or ‘severe; on both scales.
Mirvaso was found to be more effective
(p<0.001) in the reduction of facial
erythema of rosacea than vehicle when
applied once daily for 29 days. Mirvaso
demonstrated sustained efficacy for up
to 12 hours (p<0.001).
Links Archive Australian Pharmacist October 2014 Australian Pharmacist August 2014 Navigation Previous Page Next Page